Overview
STAT quoted Anthony Anscombe in an article titled "A Spate of New Class-Action Lawsuits Threaten the CBD Industry. Will They Force Washington to Act?" They article, published January 3, discusses two major lawsuits recently filed against two of the largest manufacturers of CBD, the marijuana-adjacent oil, in the country. The plaintiffs allege that the companies engaged in "false, fraudulent, unfair, deceptive, and misleading" marketing of their CBD products by claiming they were run-of-the-mill dietary supplements. The Food and Drug Administration (FDA) has already warned consumers that it is currently illegal to label CBD products as dietary supplements.
"The defendants in these cases don't need to get their checkbooks out yet," Anscombe says. He argues that while the companies might be breaking the FDA's rules, that doesn’t necessarily mean consumers didn't get some value out of these products.
The full article can be read at STAT.
